Drugs /

bupropion

Back to Drugs List

Overview

NCI Definition [1]:
An aminoketone with antidepressant activity. The molecular mechanism of the antidepressant effect of bupropion is unknown. This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine.

Clinical Trials

View Clinical Trials for bupropion

Bupropion has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bupropion, 1 is phase 1 (1 open).

BRAF V600E and BRAF V600K are the most frequent biomarker inclusion criteria for bupropion clinical trials.

Malignant solid tumor is the most common disease being investigated in bupropion clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bupropion
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bupropion and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bupropion, 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, amfebutamone, bupropion, bupropion (product), (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone, bupropion [chemical/ingredient], 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, amfebutamon, amfebutamone, bupropion, bupropion (substance)
NCIT ID [1]:
C62012
SNOMED ID [1]:
F-61C6A

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.